Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 960-969

  Edwards, James R ^a,b   Perrien, Daniel S ^a,c   Fleming, Nicole ^a   Nyman, Jeffry S ^a,d   Ono, Koichiro ^a   Connelly, Linda ^e   Moore, Megan M ^a   Lwin, Seint T ^a,b   Yull, Fiona E ^e   Mundy, Gregory R ^a,c,d,e   Elefteriou, Florent ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; NF B; osteoblast; osteoclast; SirT1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOZYME; SILENT INFORMATION REGULATOR PROTEIN; SILENT INFORMATION REGULATOR T 1 PROTEIN; UNCLASSIFIED DRUG; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE DELETION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ACETYLATION; ANATOMY AND HISTOLOGY; ANIMAL; ANTIBODY SPECIFICITY; BONE; GENE SILENCING; METABOLISM; ORGAN SIZE;

ACETYLATION; AGING; ANIMALS; BONE AND BONES; BONE REMODELING; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; I-KAPPA B PROTEINS; MICE; NF-KAPPA B; ORGAN SIZE; ORGAN SPECIFICITY; OSTEOBLASTS; OSTEOCLASTS; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84875309133     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1824     Document Type: Article

References (57)

1. Lips P, Courpron P, Meunier PJ., Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res. 1978; 26: 13-7.
2. Seeman E, Hopper JL, Young NR, Formica C, Goss P, Tsalamandris C., Do genetic factors explain associations between muscle strength, lean mass, and bone density? A twin study. Am J Physiol. 1996; 270: E320-7.
3. Herskind AM, McGue M, Holm NV, Sorensen TI, Harvald B, Vaupel JW., The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870-1900. Hum Genet. 1996; 97: 319-23.
4. Hjelmborg J, Iachine I, Skytthe A, Vaupel JW, McGue M, Koskenvuo M, Kaprio J, Pedersen NL, Christensen K., Genetic influence on human lifespan and longevity. Hum Genet. 2006; 119: 312-21.
5. Mitchell BD, Hsueh WC, King TM, Pollin TI, Sorkin J, Agarwala R, Schaffer AA, Shuldiner AR., Heritability of life span in the Old Order Amish. Am J Med Genet. 2001; 102: 346-52.
6. Kaeberlein M, McVey M, Guarente L., The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999; 13: 2570-80.
7. Rogina B, Helfand SL., Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA. 2004; 101: 15998-6003.
8. Tissenbaum HA, Guarente L., Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001; 410: 227-30.
9. Frye RA., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000; 273: 793-8.
10. Haigis MC, Guarente LP., Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006; 20: 2913-21.
11. Gan L, Mucke L., Paths of convergence: sirtuins in aging and neurodegeneration. Neuron. 2008; 58: 10-4.
12. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG., Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007; 317 (5837): 516-9.
13. Yeung F, Hoberg JE, Ramse CS, Keller MD, Jones DR, Frye RA, Mayo MW., Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J. 2004; 23: 2369-80.
14. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L., SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem. 2005; 280: 40364-74.
15. Edwards JR, Mundy GR., Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol. 2011; 7: 235-43.
16. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R., Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997; 3: 1285-9.
17. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T., Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol. 1999; 163: 434-42.
18. Wei S, Teitelbaum SL, Wang MW, Ross FP., Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology. 2001; 142: 1290-5.
19. Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP., Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res. 2005; 20: 1659-68.
20. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY., Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 2009; 15: 682-9.
21. He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, Breyer MD, Hao CM., Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010; 120 (4): 1056-68.
22. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF., Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA. 2003; 100: 10794-9.
23. Chen CL, Singh N, Yull FE, Strayhorn D, Van Kaer L, Kerr LD., Lymphocytes lacking I kappa B-alpha develop normally, but have selective defects in proliferation and function. J Immunol. 2000; 165: 5418-27.
24. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, Sadikot RT, Christman JW, Yull FE, Blackwell TS., Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006; 176: 4995-5005.
25. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I., Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999; 8: 265-77.
26. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, Mina M, Kream BE., Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol. 2004; 48: 645-53.
27. Erben RG., Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem. 1997; 45: 307-13.
28. Helenius M, Hanninen M, Lehtinen SK, Salminen A., Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor-kappa B. Biochem J. 1996; 318 (Pt 2): 603-8.
29. Korhonen P, Helenius M, Salminen A., Age-related changes in the regulation of transcription factor NF-kappa B in rat brain. Neurosci Lett. 1997; 225: 61-4.
30. Helenius M, Kyrylenko S, Vehvilainen P, Salminen A., Characterization of aging-associated up-regulation of constitutive nuclear factor-kappa B binding activity. Antioxid Redox Signal. 2001; 3: 147-56.
31. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, Lansdorp PM, Lemieux M., The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol. 2003; 23: 38-54.
32. Elefteriou F, Yang X., Genetic mouse models for bone studies-Strengths and limitations. Bone. 2011; 49: 1242-54.
33. Henriksen K, Leeming DJ, Byrjalsen I, Nielsen RH, Sorensen MG, Dziegiel MH, Martin TJ, Christiansen C, Qvist P, Karsdal MA., Osteoclasts prefer aged bone. Osteoporos Int. 2007; 18: 751-9.
34. Raisz LG., Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005; 115: 3318-25.
35. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009; 458 (7241): 1056-60.
36. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J., AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009; 458: 1056-60.
37. Gerhart-Hines Z, Dominy JE Jr, Blattler SM, Jedrychowski MP, Banks AS, Lim JH, Chim H, Gygi SP, Puigserver P., The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell. 2011; 44: 851-63.
38. Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T., SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 2010; 38: 7458-71.
39. Canto C, Auwerx J., Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol Rev. 2012; 64: 166-87.
40. Eriksen EF., Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. 1986; 7: 379-408.
41. Yuan HF, Zhai C, Yan XL, Zhao DD, Wang JX, Zeng Q, Chen L, Nan X, He LJ, Li ST., et al. SIRT1 is required for long-term growth of human mesenchymal stem cells. J Mol Med (Berl). 2012; 90: 389-400.
42. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, Long Y, Zhao J, Pei G., Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell. 2011; 10: 908-11.
43. Backesjo CM, Li Y, Lindgren U, Haldosen LA., Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res. 2006; 21: 993-1002.
44. Lee YM, Shin SI, Shin KS, Lee YR, Park BH, Kim EC., The role of sirtuin 1 in osteoblastic differentiation in human periodontal ligament cells. J Periodontal Res. 2011; 46: 712-21.
45. Tseng PC, Hou SM, Chen RJ, Peng HW, Hsieh CF, Kuo ML, Yen ML., Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res. 2011; 26: 2552-63.
46. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM., Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005; 65: 9943-52.
47. Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D'Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R., Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology. 2011; 152 (12): 4514-24.
48. Jeong JY, Silver M, Parnes A, Nikiforow S, Berliner N, Vanasse GJ., Resveratrol ameliorates TNFalpha-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-kappaB signalling. Br J Haematol. 2011; 155: 93-101.
49. Su JL, Yang CY, Zhao M, Kuo ML, Yen ML., Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem. 2007; 282: 19385-98.
50. Kupisiewicz K, Boissy P, Abdallah BM, Hansen FD, Erben RG, Savouret JF, Soe K, Andersen TL, Plesner T, Delaisse JM., Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif Tissue Int. 2010; 87: 437-49.
51. Lei M, Wang JG, Xiao DM, Fan M, Wang DP, Xiong JY, Chen Y, Ding Y, Liu SL., Resveratrol inhibits interleukin 1beta-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-kappaB activity. Eur J Pharmacol. 2012; 674: 73-9.
52. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, Xu D., Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis. 2012; 71: 129-35.
53. Yu W, Fu YC, Wang W., Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012; 113: 752-9.
54. Yi CO, Jeon BT, Shin HJ, Jeong EA, Chang KC, Lee JE, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS., Resveratrol activates AMPK and suppresses LPS-induced NF-kappaB-dependent COX-2 activation in RAW 264.7 macrophage cells. Anat Cell Biol. 2011; 44 (3): 194-203.
55. Lombard DB, Pletcher SD, Canto C, Auwerx J., Ageing: longevity hits a roadblock. Nature. 2011; 477: 410-1.
56. Viswanathan M, Guarente L., Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature. 2011; 477: E1-2.
57. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14 (5): 612-22.